PROMOTUS founder member, CurePSP, Appoints Vice President – Scientific Affairs

Updated: Apr 26

Hire will expand foundation’s neurodegeneration research

NEW YORK (January 22, 2020) – CurePSP, the foundation for prime of life neurodegeneration, has appointed Kristophe J. Diaz, PhD, as its Vice President – Scientific Affairs.

In his position, Dr. Diaz will direct the foundation’s Venture Grants program, which provides grants for research into frontotemporal disorders including progressive supranuclear palsy (PSP). Dr. Diaz will also be responsible for cultivating research partnerships with the pharmaceutical and biotech industries, government agencies, foundations and other private funders, and related nonprofit organizations.

“We are excited about having Kristophe join our team and look forward, under his leadership, to expanding our role in supporting research in neurodegeneration, which is one of the great healthcare challenges of the 21st century,” said David Kemp, President of CurePSP.

Dr. Diaz said, “I am eager to play a key role in the growth of CurePSP as it has moved from being a small rare-disease foundation to a central position in neurodegeneration research, from bench to bedside.”

Dr. Diaz was most recently senior scientific program manager at Cohen Veterans Bioscience, Cambridge, Mass., where he directed scientific and computational programs in trauma-related brain disorders. He received his PhD degree in molecular and cellular biology at the University of Massachusetts, Boston; his master’s degree in biochemistry and molecular biology at Université du Québec, Montreal; and his BA degree in molecular biology and genetics at Université de Montpellier (France).

According to the National Institutes of Health (NIH), frontotemporal disorders, including PSP, account for half of all neurodegeneration under age 65. Recent research has shown that the pathology of these diseases is linked to more-common Alzheimer’s disease, which afflicts some six million people in the U.S. alone, according to the Alzheimer’s Association.


Recent Posts

See All

Research paper in JAMA Neurology

In December, PSPA, the UK Association for people with PSP and CBD published initial results from the PROSPECT study which it funds. PROSPECT is a longitudinal research programme which uses MRI scannin

Good news from France

We are glad to inform community that clinical trial for AZP2006 (ALZPROTECT biotech) involving 36 patients for a called "phase 2a", has eventually started and and will recruit until spring 2021. AZP20

  • Twitter